Last reviewed · How we verify
IlUVIEN
IlUVIEN, marketed by the Association for Innovation and Biomedical Research on Light and Image, holds a niche position in the ophthalmic market with its unique mechanism of action. The drug's key strength lies in its key composition patent, which is set to expire in 2028, providing a period of exclusivity and potential revenue protection. The primary risk to IlUVIEN is the lack of clear primary indication and revenue data, which may limit its market penetration and investor confidence.
At a glance
| Generic name | IlUVIEN |
|---|---|
| Also known as | Fluocinolone Acetonide, Fluocinolone Acetonide Intravitreal Implant 0.19 mg |
| Sponsor | Association for Innovation and Biomedical Research on Light and Image |
| Modality | Small molecule |
| Phase | FDA-approved |
Approved indications
Common side effects
Key clinical trials
- The Therapeutic Effect of Curcumin in Nanogels Compared to 0.1% FAO in the Management of Oral Lichen Planus (NA)
- Frequency and Intensity of Inflammatory Relapses in Patients With Non-infectious Posterior Uveitis Treated With a Fluocinolone Acetonide Implant
- Imaging of Uveitis Patients Receiving Injectable Fluocinolone Acetonide Implant
- Intravitreal Faricimab Injections or Fluocinolone Acetonide (0.19 mg) Intravitreal Implants vs Observation for Prevention of VA Loss Due to Radiation Retinopathy (PHASE3)
- Comparison of Efficacy of Metformin Gel 30% vs Triple Combination Cream (Hydroquinone 4%, Flucinolone Acetonide 0.01%, Tretinoin 0.025%) in Treatment of Melasma in Tertiary Care Hospital Karachi (NA)
- A Study to Evaluate Upadacitinib in Combination With Topical Corticosteroids in Adolescent and Adult Participants With Moderate to Severe Atopic Dermatitis (PHASE3)
- Baricitinib Versus Azathioprine in Patients With Moderate-to-Severe Atopic Dermatitis (NA)
- Effect of Lidocaine-Dexmedetomidine on Pain, Inflammation, and Oxidative Stress After Bariatric Surgery. (PHASE4)
Primary sources
Every claim on this page is sourced from regulatory or scientific primary sources. See our editorial policy for full methodology.
| Source | Used for |
|---|---|
| ClinicalTrials.gov | Trial enrolment, design, endpoints, results |
Competitive intelligence
For the full competitive landscape — auto-detected comparators, recent regulatory actions across the set, upcoming PDUFA, patent timeline, sponsor landscape:
- IlUVIEN CI brief — competitive landscape report
- IlUVIEN updates RSS · CI watch RSS
- Association for Innovation and Biomedical Research on Light and Image portfolio CI